Traders Buy High Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the target of some unusual options trading on Tuesday. Stock traders acquired 17,427 put options on the stock. This is an increase of 207% compared to the average volume of 5,683 put options.

Capricor Therapeutics Trading Up 11.5%

Shares of Capricor Therapeutics stock opened at $6.20 on Wednesday. The stock has a market capitalization of $283.45 million, a price-to-earnings ratio of -3.78 and a beta of 0.57. Capricor Therapeutics has a 1-year low of $5.43 and a 1-year high of $20.75. The firm has a fifty day simple moving average of $6.56 and a 200-day simple moving average of $8.28.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). As a group, research analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $28,000. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $36,000. Tower Research Capital LLC TRC boosted its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in Capricor Therapeutics during the 1st quarter worth $95,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at $99,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

CAPR has been the topic of several recent analyst reports. Roth Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.38.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.